76408-71-4

Basic information

• Product Name: l-Cysteine, S-[(acetylamino)methyl]-N-[N-[N-[N-[N-[N6-[[2-(methylsulfonyl)ethoxy]carbonyl]-l-lysyl]-l-threonyl]-l-phenylalanyl]-l-threonyl]-l-seryl]-, 2-[[[4-(phenylazo)phenyl]methyl]sulfonyl]ethyl ester, mono(trifluoroacetate) (salt)
• Synonyms: l-Cysteine, S-[(acetylamino)methyl]-N-[N-[N-[N-[N-[N6-[[2-(methylsulfonyl)ethoxy]carbonyl]-l-lysyl]-l-threonyl]-l-phenylalanyl]-l-threonyl]-l-seryl]-, 2-[[[4-(phenylazo)phenyl]methyl]sulfonyl]ethyl ester, mono(trifluoroacetate) (salt)
• CAS NO: 76408-71-4
• Molecular Formula: C₂HF₃O₂*C₅₁H₇₂N₁₀O₁₇S₃
• Molecular Weight: 1307.3925296
• EINECS: 278-449-9
• Mol File: 76408-71-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 1556.4°C at 760 mmHg
• Flash Point: 895.1°C
• Appearance: /
• Vapor Pressure: 0mmHg at 25°C
• CAS DataBase Reference: l-Cysteine, S-[(acetylamino)methyl]-N-[N-[N-[N-[N-[N6-[[2-(methylsulfonyl)ethoxy]carbonyl]-l-lysyl]-l-threonyl]-l-phenylalanyl]-l-threonyl]-l-seryl]-, 2-[[[4-(phenylazo)phenyl]methyl]sulfonyl]ethyl ester, mono(trifluoroacetate) (salt)(CAS DataBase Reference)
• NIST Chemistry Reference: l-Cysteine, S-[(acetylamino)methyl]-N-[N-[N-[N-[N-[N6-[[2-(methylsulfonyl)ethoxy]carbonyl]-l-lysyl]-l-threonyl]-l-phenylalanyl]-l-threonyl]-l-seryl]-, 2-[[[4-(phenylazo)phenyl]methyl]sulfonyl]ethyl ester, mono(trifluoroacetate) (salt)(76408-71-4)
• EPA Substance Registry System: l-Cysteine, S-[(acetylamino)methyl]-N-[N-[N-[N-[N-[N6-[[2-(methylsulfonyl)ethoxy]carbonyl]-l-lysyl]-l-threonyl]-l-phenylalanyl]-l-threonyl]-l-seryl]-, 2-[[[4-(phenylazo)phenyl]methyl]sulfonyl]ethyl ester, mono(trifluoroacetate) (salt)(76408-71-4)

Safety Data

• Hazardous Substances Data: 76408-71-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C51H72N10O17S3.C2HF3O2/c1-32(63)43(58-45(66)39(52)17-11-12-22-53-51(72)78-23-25-80(4,73)74)48(69)55-40(27-35-13-7-5-8-14-35)46(67)59-44(33(2)64)49(70)56-41(28-62)47(68)57-42(29-79-31-54-34(3)65)50(71)77-24-26-81(75,76)30-36-18-20-38(21-19-36)61-60-37-15-9-6-10-16-37;3-2(4,5)1(6)7/h5-10,13-16,18-21,32-33,39-44,62-64H,11-12,17,22-31,52H2,1-4H3,(H,53,72)(H,54,65)(H,55,69)(H,56,70)(H,57,68)(H,58,66)(H,59,67);(H,6,7)/t32?,33?,39-,40-,41-,42-,43-,44-;/m0./s1

Upstream product

• 76408-69-0 BOC-Lys(MSC)-Thr-Phe-Thr-Ser-Cys(ACM)-OPSE 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 76408-72-5 BOC-D-Trp-Lys(MSC)-Thr-Phe-Thr-Ser-Cys(ACM)-OPSE 

Relevant articles and documents

New analogs of somatostatin with unexpected effects in vivo on insulin basal secretion in the rat

Twenty analogs of somatostatin were synthesized by the alternating solution/solid-phase procedure. The peptide analogs contained taurine, aza-alanine, or D-amino acids as well as multiple deletions. The aim of this study was to obtain analogs that would selectively inhibit insulin or glucagon release. The biological activities were evaluated in vivo in the rat by measuring the effects of the modified somatostatin molecules on basal secretion of insulin and glucagon in the portal vein. Although some selective analogs were found, a few of them having a taurine or an aza-alanine residue in their structure caused a significant increase of insulin secretion. This unexpected phenomenon, for which we do not have an explanation at present, is under investigation.